PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today a ...

The current quarter saw a transition from exploring strategic alternatives and foundational pre-commercialization work (as described in Q4 2024) to active launch preparations and a clearly stated ...

A federal appeals court partially upheld a decision from the National Labor Relations Board against two movie production ...